<DOC>
	<DOCNO>NCT00002989</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness idarubicin plus peripheral stem cell transplantation use patient 's donated stem cell treat patient leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Idarubicin Peripheral Stem Cell Transplantation Treating Patients With Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I. Assess value idarubicin add standard condition regimen allogeneic autologous stem cell transplantation patient leukemia myelodysplastic syndrome high risk relapse . II . Determine time recovery polymorphonuclear neutrophil leukocyte ( PMN ) platelet count patient . III . Evaluate rate type grade 3-4 toxicity , particularly mucositis , number day fever patient . IV . Determine incidence acute chronic graft versus host disease ( GVHD ) patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease ( acute myelogenous leukemia ( AML ) v acute lymphocytic leukemia ( ALL ) lymphoblastic leukemia ( LL ) v myelodysplastic syndrome ( MDS ) secondary AML v chronic myelogenous leukemia ( CML ) vs non-Hodgkin 's lymphoma v multiple myeloma ) , stage disease ( CML , 1st complete response ( CR ) vs 2nd CR v 1st/2nd CR ; CML , 1st CR v phase ) , condition regimen ( cyclophosphamide ( CTX ) total body irradiation ( TBI ) v busulfan ( BU ) CTX v ) , source donor ( allogeneic vs autologous ) , T-cell depletion autologous transplantation ( vs yes ) , source stem cell ( bone marrow v peripheral blood stem cell ) . Patients randomize receive standard regimen intensify regimen . Standard pretransplant treatment : CTX day -6 -5 TBI day -4 -2 , BU day -8 -5 CTX day -4 -3 , BU day -8 -5 melphalan IV day -4 . Intensified pretransplant regimen : I . Continuous infusion idarubicin ( IDA ) 48 hour day -12 -11 , follow 5 day later CTX day -6 -5 TBI day -4 -2 II . IDA follow 5 day later BU day -8 -5 , CTX day -4 -3 III . IDA follow BU day -8 -5 melphalan IV day -4 . Stem cell infuse day 0 . Patients follow every 3 month first 3 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 207 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myelogenous leukemia ( AML ) , acute lymphocytic leukemia ( ALL ) , lymphocytic leukemia ( LL ) myelodysplastic syndrome ( MDS ) least one follow high risk criterion : Tcell deplete stem cell autologous stem cell Second complete response ( CR ) Previous CNS involvement No CR First CR achieve 5 week start remissioninduction therapy Poor prognostic cytogenetic feature : ( 9 ; 22 ) , ( 8 ; 14 ) , ( 11 ; 14 ) , 11q23 anomaly , 5/5qanomalies , 7/7qanomalies , +8 , complex cytogenetics Postcytotoxic/secondary AML Chronic myelogenous leukemia ( CML ) least one follow high risk criterion : Tcell deplete stem cell Not first chronic phase NonHodgkin 's lymphoma multiple myeloma Autologous stem cell PATIENT CHARACTERISTICS : Age : 16 60 Performance status : WHO 02 Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No severe heart failure require diuretic No ejection fraction le 50 % Neurologic : No severe concurrent neurological psychiatric disease Other : HIV negative No allogeneic stem cell donor HLA identical sibling ( ) PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>